Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZP5-9676
- Development stage
- Phase 3
- Lead developer
- Zero Point Five Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZP5-9676 is a small molecule anthelmintic drug candidate developed by Zero Point Five Therapeutics for the treatment of soil-transmitted helminthiasis, including infections caused by *Ascaris* (roundworm), *Trichuris* (whipworm), *Necator americanus*, and *Ancylostoma duodenale* (hookworms). It is designed as a single-dose therapy with a child-friendly formulation that remains localized in the intestine to minimize systemic exposure and enhance safety, particularly for pediatric populations. The precise mechanism of action has not been disclosed. ZP5-9676 is currently in Phase 3 clinical trials for helminthiasis in both pediatric and adult patients.
Beyond the preview
Go deeper on ZP5-9676.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZP5-9676.